Summary:
- This article discusses the importance of transparency and accountability in the psychedelics industry, particularly in the aftermath of a patient's death during a clinical trial or treatment.
- It highlights the need for open communication, thorough investigations, and learning from such tragic events to improve patient safety and build public trust in the responsible use of psychedelics.
- The article emphasizes that transparency alone cannot solve all the challenges, but it can play a crucial role in fostering a culture of safety, learning, and continuous improvement within the psychedelics community.